What is the fair value of Kamada (NASDAQ-KMDA) stock?

The current fair value estimate for Kamada (NASDAQ-KMDA) is $9.03. This implies an estimated upside of 24.7% versus the current market price.

Is Kamada (NASDAQ-KMDA) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 24.7% versus the current market price.

What is the analyst price target for NASDAQ-KMDA stock?

The available analyst price target for Kamada (NASDAQ-KMDA) is $13. The analyst target implies estimated upside of 79.4%.

How is the financial health of Kamada?

The current financial health read for Kamada (NASDAQ-KMDA) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Kamada's next earnings date?

The next earnings date currently listed for Kamada (NASDAQ-KMDA) is August 19, 2026.

Does Kamada (NASDAQ-KMDA) pay dividends?

Based on the current data, dividend yield is 3.5%, upcoming dividend amount is 0.25.

What is the P/E ratio for Kamada (NASDAQ-KMDA)?

The current P/E ratio listed for Kamada (NASDAQ-KMDA) is 20.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Kamada?

The current market capitalization listed for Kamada is 414.7 M.

What is the enterprise value of Kamada?

The current enterprise value listed for Kamada is 352.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Kamada?

The ticker symbol for Kamada is NASDAQ-KMDA, and the stock is listed on NASDAQ.

Where is Kamada (NASDAQ-KMDA) listed?

Kamada (NASDAQ-KMDA) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Kamada?

The current debt-to-total-capital ratio listed for Kamada is 2.7%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Kamada?

The free float listed for Kamada is 54.5%. Free float helps investors understand how much of the share base is available for public trading.

Kamada (KMDA) Fair Value & Stock Analysis

Kamada (KMDA)

Kamada Ltd. is a biotechnology company engaged in the manufacture and sale of plasma-derived protein therapeutics. Its portfolio includes products used in areas such as rabies prophylaxis, transplant-related Cytomegalovirus prevention, varicella post-exposure prophylaxis, immune thrombocytopenic purpura, hepatitis B prevention, alpha-1 antitrypsin deficiency, and treatment of snake bites. The company also distributes a range of biopharmaceutical products in Israel, covering respiratory, immunology, hematology, infectious disease, and oncology-related therapies. Founded in 1990 and headquartered in Rehovot, Israel, Kamada’s common stock is listed on the NASDAQ exchange under the symbol KMDA.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
NASDAQ-KMDA	$9.03	24.7% Upside	Undervalued	$13	79.4% Upside	Bargain	Great	—	—	0.25	3.5%	August 19, 2026	20.5x	1.6x	2.3x	414.7 M	352.9 M	2.7%	54.5%	9.3	56.6%	80.3%